Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753468 | 0.98 | GAA (0.35) | GAAALDH1A1TP53SMN1; SMN2CYP3A4 | |
| SCHEMBL753467 | 0.98 | GAA (0.35) | GAAALDH1A1TP53SMN1; SMN2CYP3A4 | |
| SCHEMBL20342326 | 0.87 | CYP2A6 (0.38) | GAAALDH1A1SMN1; SMN2TSHRNPC1 | |
| SCHEMBL20342337 | 0.83 | CYP2A6 (0.50) | GAAALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL9976852 | 0.83 | GAA (0.35) | GAAALDH1A1TP53SMN1; SMN2CYP3A4 | |
| SCHEMBL754841 | 0.82 | CYP2A6 (0.34) | GAAALDH1A1TP53SMN1; SMN2CYP3A4 | |
| SCHEMBL20342390 | 0.81 | ILK (0.31) | — | |
| SCHEMBL754864 | 0.81 | CYP2A6 (0.36) | GAAALDH1A1TP53SMN1; SMN2CYP3A4 | |
| SCHEMBL13556946 | 0.79 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL11976505 | 0.78 | GAA (0.42) | GAAALDH1A1TP53SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138355-B2 | Heteroacene derivative, tetrahaloterphenyl derivative, and processes for producing the same | TOSOH CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090261300-A1 | HETEROACENE DERIVATIVE, TETRAHALOTERPHENYL DERIVATIVE, AND PROCESSES FOR PRODUCING THE SAME | TOSOH CORPORATION (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090261300-A1 | HETEROACENE DERIVATIVE, TETRAHALOTERPHENYL DERIVATIVE, AND PROCESSES FOR PRODUCING THE SAME | AS3MT, TERT, TEAD1 | GAA 4119/4885ALDH1A1 2196/4885TP53 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.